Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19.
Eur J Hosp Pharm. 2021 Apr 8:ejhpharm-2020-002667. doi: 10.1136/ejhpharm-2020-002667. Online ahead of print.
Eur J Hosp Pharm. 2021.
PMID: 33832918